首页> 外文期刊>Human vaccines >Hepatitis A vaccine should receive priority in national immunization schedule in India
【24h】

Hepatitis A vaccine should receive priority in national immunization schedule in India

机译:印度应将甲型肝炎疫苗列为国家免疫计划的重点

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatitis A is an acute, usually self-limiting infection of the liver caused by a virus known as hepatitis A virus (HAV). Humans are the only reservoir of the virus; transmission occurs primarily through the fecal-oral route and is closely associated with poor sanitary conditions. The virus has a world-wide distribution and causes about 1.5 million cases of clinical hepatitis each year. The risk of developing symptomatic illness following HAV infection is directly correlated with age. As many 85% of children below 2 y and 50% of those between 2-5 y infected with HAV are anicteric, and among older children and adults, infection usually causes clinical disease, with jaundice occurring in more than 70% of cases. The infection is usually self-limiting with occasional fulminant hepatic failure and mortality. In most developing countries in Asia and Africa, hepatitis A is highly endemic such that a large proportion of the population acquires immunity through asymptomatic infection early in life. HAV is endemic in India; most of the population is infected asymptomatically in early childhood with life-long immunity. Several outbreaks of hepatitis A in various parts of India have been recorded in the past decade such that anti-HAV positivity varied from 26 to 85%. Almost 50% of children of ages 1-5 y were found to be susceptible to HAV. Any one of the licensed vaccines may be used since all have nearly similar efficacy and safety profiles (except for post-exposure prophylaxis / immunocompromised patients, where only inactivated vaccines may be used). Two doses 6 mo apart are recommended for all vaccines. All Hepatitis A vaccines are licensed for use in children aged 1 y or older. However in the Indian scenario, it is preferable to administer the vaccines at age 18 mo or more when maternal antibodies have completely declined. Vaccination at this age is preferable to later since it is easier to integrate with the existing schedule, protects those who have no antibodies, and protects children by the time they attend day care. In India the vaccine against hepatitis A is available for the people who can afford it, but the government of India should give this vaccine as a priority in the national immunization schedule.
机译:甲型肝炎是由称为甲型肝炎病毒(HAV)的病毒引起的急性肝病,通常是自限性感染。人类是该病毒的唯一储存库。传播主要通过粪口途径发生,与卫生条件差密切相关。该病毒在世界范围内分布,每年引起约150万例临床肝炎病例。 HAV感染后出现症状性疾病的风险与年龄直接相关。在2岁以下的儿童中,有多达85%的儿童感染HAV,而在2-5岁之间的儿童中,有50%的儿童为抗风湿性关节炎,在较大的儿童和成年人中,感染通常会引起临床疾病,其中70%以上的病例会发生黄疸。感染通常是自限性的,偶发性暴发性肝衰竭和死亡。在亚洲和非洲的大多数发展中国家,甲型肝炎是高度流行的,因此很大一部分人口在生命早期就通过无症状感染获得了免疫力。 HAV在印度很流行。大多数人口在儿童早期就被无症状感染,具有终身免疫力。在过去的十年中,印度各地爆发了几起甲型肝炎的暴发,抗-HAV阳性率从26%到85%不等。发现1-5岁儿童中几乎有50%容易感染HAV。可以使用任何一种许可疫苗,因为所有疫苗都具有几乎相似的功效和安全性(暴露后预防/免疫功能低下的患者除外,其中只能使用灭活的疫苗)。对于所有疫苗,建议间隔6个月服用两次。所有A型肝炎疫苗均许可用于1岁或以上的儿童。但是,在印度情况下,当母源抗体完全下降时,最好在18 mo或更高的年龄接种疫苗。在这个年龄进行疫苗接种要晚一些,因为它可以更容易地与现有的日程安排结合起来,保护那些没有抗体的人,并在儿童参加日托时保护他们。在印度,有能力的人可以买到抗A型肝炎的疫苗,但印度政府应将这种疫苗作为国家免疫计划的优先事项。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号